Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period March 8, 2019 through March 8, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 46 segments, totaling 2.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
2.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the understanding and application of PCSK9 inhibitor-based therapies in the management of hypercholesterolemia.
March 8, 2019
March 8, 2021
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients who have high levels of LDL-C, including cardiologists, interventional cardiologists, lipid specialists, atherosclerosis specialists, diabetes specialists, endocrinologists, and related clinicians.
Participation in this iQ&A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
This activity is supported by an independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine and CMEducation Resources, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the Postgraduate Institute for Medicine to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the Postgraduate Institute for Medicine are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Program Faculty and Disclosure
Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, The Medicines Company
Keith A.A. Fox, MBChB, FRCP, FMedSci
Professor, University of Edinburgh
Department of Cardiovascular Medicine
Professor, University and Royal Infirmary
Edinburgh, United Kingdom
Consultant: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi
Speaker: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals
Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA
Associate Head, Division of Cardiology
St. Michael’s Hospital
Professor, Department of Medicine
University of Toronto
Consulting: Amgen, Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, Merck, Pfizer
Speaker: Amgen, Sanofi, Regeneron
Research Support: Amgen, Sanofi, Regeneron
J. Wouter Jukema, MD, PhD, FESC, FACC MC
Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Research Support or CME Speaker Fees: Amgen, Astra-Zeneca, Biotronik, Daiichi Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis, The Medicine Company, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Interuniversity Cardiology Institute of the Netherlands, and the European Community Framework KP7 Program
Ulf Landmesser MD, FESC
Professor of Cardiology
Medical Director, Department of Cardiology
Charite University Hospital
Consultant: Sanofi, Amgen, Medicines Company
Paul Ridker, MD
Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Consultant: Corvidia; Eisai Inc.; Inflazome Ltd.; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Quintiles Transnational Corp.; Sanofi
Research Suport: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Kowa Company Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Other: Co-inventor on patents licensed to AstraZeneca Pharmaceuticals LP and Siemens AG
Phillipe Gabriel Steg, MD
Professor of Cardiology
Université Paris – Diderot, Sorbonne-Paris Cité
Professor, National Heart and Lung Institute
Imperial College, London, UK
Director, Coronary Care Unit
Advisor or consultant: Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; SERVIER
Speaker: Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; SERVIER
Research Support: Bayer HealthCare Pharmaceuticals; Merck & Co., Inc.; Sanofi; SERVIER
Professor Andreas Zeiher, MD
Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Consultant: Sanofi, Amgen, Boehringer Ingelheim
Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD has nothing to disclose.
Upon completion of this activity, participants will be able to:
- Outline the design, results, and outcomes of landmark cardiovascular outcome clinical trials (CVOTs) addressing the safety and efficacy of non-statin therapies for medical management of high risk patients with elevated LDL-C, including those patients with a prior recent ACS event and/or advanced ASCVD accompanied by poorly controlled LDL-C levels
- Screen for suboptimal LDL-C levels and indentify high risk groups with risk factors and/or a previous history of CAD/ASHD—including individuals with recent ACS, familial hypercholesterolemia, history of ASHD, and/or diabetes—who are appropriate candidates for PCSK9 inhibition
- Apply evidenced-based, scientifically substantiated international (AHA, ACC, ESC/EAS) guideline recommendations and clinical decision tree pathways and international consensus guidelines and recommendations for treating patients with LDL-C levels that require lowering to optimize clinical outcomes
- Outline the pharmacoeconomic impact and implications of deploying PCSK9 inhibitors to reduce MACE events and mortality of patients according to LDL-C levels (less or greater than 100 mg/dL) and how such stratifications effect recommendations by ICER, AHA and other organizations evaluating the pharmacoeconomic metrics PCSK9 inhibitors, both on an individual and class basis
- Discuss and interpret the evidence supporting the safety and outcome-linked benefits of lowering LDL-C as a primary strategy to decrease cardiovascular risk for a wide range of patients with persistent or inadequately controlled hypercholesterolemia
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Copyright © 2019 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC